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Determination of optimal method for antibody 
identification in a reference laboratory
J.R. Haywood, M.K.G. Moulds, and B.J. Bryant
Methods commonly used for antibody identification are 
hemagglutination (tube), column agglutination (gel), and solid-
phase red cell adherence. Our AABB immunohematology 
reference laboratory (IRL) conducted a study to determine 
which antibody identification testing method was optimal for 
detecting all clinically significant antibodies. Patient specimens 
were sent to our IRL from August 2008 to September 2009. 
Routine testing was performed by tube method and then by 
manual gel and manual solid-phase methods. Of the 254 samples 
tested, 115 showed agreement in antibody identification with all 
three methods. The tube method identified all but six clinically 
significant antibodies. The gel method did not identify 59 
clinically significant antibodies. Fifty-six clinically significant 
antibodies were not identified by solid-phase testing. Tube testing 
identified 27 clinically insignificant antibodies, primarily cold 
autoantibodies. Gel and solid-phase methodologies identified two 
and three cold autoantibodies, respectively. Solid-phase testing 
failed to detect 12 examples of anti-K. No identifiable pattern of 
reactivity was found in 13 samples using gel testing compared 
with 6 for solid-phase and none for tube methodologies. 
Hemagglutination tube method was the best choice for our IRL 
because it missed the fewest number of clinically significant 
alloantibodies. Benefits also included the ability to use various 
potentiating factors, incubation times, and temperature phases 
to enhance antibody identification. The tube method provided 
critical data for determining antibody clinical significance. 
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The three methods commonly used in the United States 
for pretransfusion testing and antibody identification are 
hemagglutination (tube), column agglutination (gel), and solid-
phase red cell adherence.1 All are effective, but usually one is 
selected by a laboratory as the primary method. Of 58 AABB 
immunohematology reference laboratories (IRLs) surveyed at 
the time of our study, 49 used tube, 7 used gel, and 2 used 
solid-phase methodologies.2 Our IRL used the tube method 
as the primary method for antibody determination, although 
most facilities we received samples from used gel or solid-
phase testing for detection, and in some cases preliminary 
identification, of antibodies before sending the specimens for 
complete identification. The aim of this study was to evaluate 
tube, gel, and solid-phase test results to determine the optimal 
method for the detection and identification of all clinically 
significant antibodies.
Materials and Methods
Patient specimens used in the study were sent to our 
reference laboratory from August 2008 until September 2009. 
The specimens came from hospitals, clinics, and dialysis 
centers that use our laboratory for antibody workups. Most 
samples referred to our IRL had incomplete or inconclusive 
antibody identifications. The majority of the referring 
laboratories used automated gel methodology (Ortho ProVue, 
Ortho Clinical Diagnostics, Inc., Rochester, NY) and others 
used automated solid-phase testing (Immucor Galileo or 
Galileo Echo, Immucor Gamma, Norcross, GA). The least 
common method used by the referring laboratories was 
tube testing. Routine testing in our IRL was performed by 
the tube method, and an aliquot of serum or plasma was 
saved for manual gel and manual solid-phase testing (aliquot 
refrigerated for testing within 24 hours or frozen for later 
testing).
Tube testing was performed using a modified tube 
testing methodology introduced by John Moulds when he 
joined LifeShare Blood Center, Shreveport, Louisiana, in 
2004 as Director of Scientific Support. Two drops of patient’s 
serum or plasma was incubated with 1 drop of reagent red 
blood cells (RBC) for 5 minutes at room temperature (RT). 
The tubes were centrifuged and read. Two drops of low ionic 
strength saline (LISS) additive (LO-ION, Immucor Gamma) 
was added to each tube; the tubes were incubated at RT 
for an additional 10 minutes before being centrifuged and 
read. The tubes were then incubated at 37°C for 30 minutes, 
centrifuged, and read. Tubes were washed four times with 
0.9 percent sodium chloride, and the last wash was decanted. 
One to two drops of anti-IgG (Gamma-Clone Anti-IgG, 
Immucor Gamma) was added to each tube, centrifuged, and 
read. Additional enhancement methods were used as needed 
depending on the initial test results, i.e., saline 60 minutes 
incubation at 37°C without enhancement, or a polyethylene 
glycol (PEG) additive (PeG, Immucor Gamma) to enhance 
orIgInal report
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weak reactions or rule out alloantibodies, or enzyme and 
chemical testing.
The manual solid-phase testing used 14-cell antibody 
identification panels (Capture-R Ready-ID, Immucor Gamma). 
Manual gel antibody identification panels used gel cards (IgG 
gel cards, Ortho Clinical Diagnostics, Inc.) with commercial 
RBCs (Panocell 10-panel, Immucor Gamma) diluted to 0.8 
percent concentration. Solid-phase and column agglutination 
(gel) methods were performed per manufacturers’ 
recommendations.
Antibody identification results of each specimen were 
sorted into one of five groups based on the findings for the 
three testing methods: all methods agree, none agree, tube 
and gel methods agree, tube and solid-phase methods agree, 
and solid-phase and gel methods agree.
Results
In a 13-month period, a total of 254 specimens were 
processed by all three methods. The three methods 
demonstrated the same antibody identification results in 115 
samples (45% of the total tested). Table 1 lists the antibodies 
identified by all three methods and the number of times these 
antibodies were found.
Solid-phase and gel methods agreed, but the tube method 
did not, in 51 samples (20%). There were 16 clinically significant 
antibodies detected by the tube method that were missed by 
both the solid-phase and gel methods. These included anti-D, 
-C, -E, -K, -Jka, and -Jkb. There was only one sample in which 
the tube method missed a clinically significant antibody, 
anti-C, which was detected by the solid-phase and gel methods 
(Table 2).
The results of the tube and gel methods agreed, but the 
solid-phase missed 15 clinically significant antibodies in 29 
samples (12% of the samples tested). The clinically significant 
Table 1. Tube, gel, and solid-phase methods agree
Antibodies detected Occurrences Antibodies detected Occurrences
Anti-C 1 Anti-e 1
Anti-c 1 Anti-E, Fya 2
Anti-c, E, s 1 Anti-E, K 2
Anti-D 13 Anti-Fya 3
Anti-D, C 2 Anti-Jka 2
Anti-D, C, E 1 Anti-K 5
Anti-D, C, Fya, Jka 1 Anti-M 1
Anti-D, C, V 1 No antibodies 58
Anti-E 10 Warm autoantibody 10
Table 2. Solid-phase and gel methods agree
Solid-phase and gel results Tube results
One cell positive Anti-E
All cells positive except one Anti-C, warm autoantibody
Anti-D Anti-D, cold autoantibody
Anti-D Anti-D, other cells positive
Anti-D, C Anti-D
Anti-D, K Anti-D, K, Jka
Anti-E Anti-E, McCa
Anti-E, Jka Anti-E, Jka, cold autoantibody
Anti-E, K, Fya Anti-E, K, Fya, cold autoantibody
Anti-E, other cells positive Anti-E, Jsa, M
Anti-K Anti-C, K, Jkb
Anti-K Anti-K, cold autoantibody
Anti-K Anti-K, M
No pattern Anti-C
No pattern Anti-C, E
No pattern Anti-D, K
No pattern Anti-E
No pattern No reactivity
No pattern No reactivity




No reactivity Anti-E, cold autoantibody
No reactivity Anti-K





No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody
No reactivity Cold autoantibody with N specificity
No reactivity Enhancement related (all positive)
No reactivity HTLA-like
No reactivity Weak reactivity
No reactivity Weak reactivity
Warm autoantibody No reactivity
HTLA = high-titer, low-avidity antibody; PEG = polyethylene glycol.
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antibodies missed by the gel method included anti-D, -E, -e, 
-K, -S, -Jka, -Jkb, and -U. However, in one sample, anti-Jka 
was identified in solid-phase, but not in tube or gel methods 
(Table 3).
Results from tube and solid-phase testing, but not gel, 
revealed the same antibodies in 23 samples (9%). Gel testing 
missed 19 significant antibodies: anti-D, -C, -c, -E, -K, -S, 
-Fya, -Jka, -Jkb, and warm autoantibody. One sample revealed 
anti-E identified by gel when it was not detectable in tube or 
solid-phase testing methods (Table 4).
None of the methods agreed in 36 samples (14%). In 
this sample cohort, the tube method missed 3 significant 
antibodies (one anti-C and two anti-E). The solid-phase 
method missed 24, and gel missed 23. Gel was the only 
method demonstrating hemolysis with two samples tested. 
There were many panels that were inconclusive, which 
complicated data analysis (Table 5).
No method captured every clinically significant antibody. 
The gel method missed 59 antibodies and seemed to give the 
most results that showed no pattern. Solid-phase testing missed 
56 antibodies. The tube method missed only 6 antibodies, but 
also identified the most insignificant antibodies, primarily 
cold autoantibodies.
Discussion
Several studies have compared various antibody detection 
and identification methods in search of the best method 
for pretransfusion serologic testing.3–5 Our study differed 
from these previous comparison studies in that it sought to 
determine the optimal routine testing methodology for the 
identification of antibodies referred to our IRL. Referring 
laboratories used various methods of pretransfusion testing; 
most used automated gel or solid-phase methods. Antibody 
workups referred to our IRL included detected but not 
identified antibodies, incomplete antibody identifications, 
and antibody workups with weak inconclusive results. The 
referring laboratories depended on the IRL to accurately and 
completely identify the detected antibodies. All three manual 
Table 3. Tube and gel methods agree
Tube and gel results Solid-phase results
All positive All positive except one cell
Anti-D Anti-D, one additional cell positive
Anti-D No reactivity
Anti-D No pattern
Anti-D, C, Jka Anti-D, C
Anti-E No reactivity
Anti-E 2 of 3 E+ cells reactive
Anti-E No reactivity
Anti-e All cells positive
Anti-E, K One cell positive (E, K neg)










Cold autoantibody No pattern
Cold autoantibody (strong) All positive except one cell
Cold autoantibody (strong) No pattern
No reactivity Anti-Jka
No reactivity No pattern
No reactivity No pattern
No reactivity Weak reactivity
Weak reactivity No reactivity
Weak reactivity No reactivity 
Table 4. Tube and solid-phase methods agree
Tube and solid-phase results Gel results
Anti-c, E, K, S, Ch (all cells positive) 3 cells negative; no pattern
Anti-C, S Anti-S
Anti-C, warm autoantibody No pattern
Anti-D 4 of 5 D+ cells positive
Anti-D, C, Jka, warm autoantibody No pattern
Anti-e 1 e+ cell negative
Anti-E, Fya No pattern
Anti-E, Fya All cells positive
Anti-E, K, Jkb Anti-E, K, few other cells positive 
(not Jkb)
Anti-Jkb Anti-Jkb, one additional cell positive
Anti-K Anti-K, other cells positive
Anti-K Anti-K, other cells positive
Anti-M One cell positive
Cold autoantibody No pattern
Cold autoantibody No pattern
Cold autoantibody No reactivity
No reactivity Weak reactivity
No reactivity 8 of 11 cells positive
No reactivity 1 cell positive
No reactivity (prev Anti-E, K) Anti-E
Warm autoantibody 6 of 11 cells positive
Warm autoantibody 7 of 11 cells positive
Warm autoantibody 8 of 11 cells positive
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testing modalities used at our IRL and evaluated in this study 
had unique performance profiles, which are summarized in 
the following sections.
Tube Method
Tube method testing missed the fewest clinically 
significant antibodies (6). This was because of the many ways 
that this method could be manipulated, such as temperature, 
time, and enhancement media. The tube method detected not 
only clinically significant antibodies, but also cold-reactive and 
insignificant antibodies. This method demonstrated the best 
sensitivity by detecting 188 clinically significant antibodies. 
However, the tube method did detect 49 insignificant 
antibodies, 30 of which were cold autoantibodies. Identification 
of cold autoantibodies is time and labor intensive, although in 
some instances, cold autoantibody identification by the tube 
method provided the cause for unexplained reactions obtained 
by the referring laboratory.
Solid-Phase Method
Solid-phase testing failed to detect 6 examples of Knops 
system antibodies. Two of these 6 antibodies were detected 
by gel testing, and all 6 were detected by tube method. In 
one sample, anti-Jka was identified by solid-phase method 
whereas tube and gel testing showed no reactivity. Solid-phase 
testing has also been shown not to detect most cold-reactive 
antibodies, although 3 were identified. Anti-K was missed 12 
times by solid-phase testing in this study, whereas gel testing 
missed 9 and tube testing missed 1. Solid-phase testing was 
also inconsistent in identifying Rh antibodies.
Gel Method
As with the solid-phase method, gel testing did not detect 
most cold-reactive antibodies, although two were identified. 
Anti-E reacted strongly in gel, but was still missed in some 
samples in which the tube method identified it. Gel testing gave 
the most results that had no specific pattern. Many antibody 
specificities were suggested but not confirmed because not 
every antigen-positive cell was reactive. Gel was the only 
method that demonstrated unexplained hemolysis during 
testing with two specimens.
One factor to consider in this analysis of multiple methods 
of antibody identification is the number of passively acquired 
anti-D antibodies resulting from Rh immune globulin (RhIG) 
administration versus true allo-anti-D. Based on antibody 
screens from hospitals, RhIG is detected uniformly in both 
automated gel and solid-phase methods. In tube testing, 
anti-D from RhIG is detected weakly, if at all.
This study did not attempt to evaluate the difference in 
antibody identification results obtained by manual versus 
automated solid-phase and gel testing. Many of the referring 
facilities used automated solid-phase and gel methods for 
Table 5. None of the testing methodologies agree
Tube results Solid-phase results Gel results
Anti-C Anti-C, other cells positive Anti-C, E
Anti-C All positive 3 of 4 C+ cells positive
Anti-c 10 of 11 c+ cells positive 5 of 7 c+ cells positive
Anti-C Anti-C, other cells positive Anti-C, E
Anti-C (PEG) No reactivity Anti-C, one other cell 
positive
Anti-c, E, Fya, 2 
other cells positive
No reactivity 3 of 10 cells positive
Anti-D Anti-D, one other cell 
positive
Anti-D, C
Anti-D, C, M Anti-D Anti-D, C, and M (dosage)
Anti-e 8 of 14 cells positive 1 cell positive
Anti-e 12 of 13 e+ cells positive No reactivity
Anti-E Anti-E, K, other cells 
positive
Anti-E
Anti-E, Jka Anti-E, 9 of 10 Jka+ cells 
positive
All positive (one E, Jka 
negative cell)
Anti-e, McCa No reactivity Hemolyzed
Anti-E, warm 
autoantibody
Anti-E, one other cell 
positive
Anti-E, 6 of 9 other cells 
positive
Anti-Jka Anti-Jka (dosage) No pattern
Anti-Jka, Yka Anti-Jka (homozygous only) No pattern
Anti-Jsb, C, K, Fya Anti-K Anti-C, K, Fya
Anti-K 1 of 3 K+ cells positive No reactivity
Anti-K No reactivity 1 of 3 K+ cells positive
Anti-K No reactivity Anti-K, other cells positive
Anti-K, Jka No reactivity Anti-K and Jka (dosage)
Anti-K, P1 Anti-K No pattern
Anti-K, warm 
autoantibody
No reactivity No pattern
Anti-M 2 cells positive No reactivity
Anti-M Anti-M (homozygous cells 
only)
No reactivity
Cold autoantibody No reactivity Hemolyzed
Cold autoantibody No reactivity 7 of 10 cells positive
Cold autoantibody 9 of 14 cells positive No reactivity
No reactivity All positive No pattern (5 cells 
positive)
No reactivity Anti-Jkb (dosage) No reactivity
No reactivity Anti-e All positive
No reactivity Anti-D No pattern
Warm autoantibody No reactivity Possible anti-C
Warm autoantibody 
(PEG)






Weak reactivity All positive 3 cells positive
PEG = polyethylene glycol.
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antibody detections and initial antibody identifications, where 
our reference laboratory used only manual methods. The 
impact of this variation is unknown.
In conclusion, this study demonstrated that the 
hemagglutination tube method was the best choice for 
antibody identification, as it missed the fewest number 
of clinically significant alloantibodies compared with the 
other two methods. A reference laboratory is responsible for 
identifying all antibodies present, whether clinically significant 
or not. Major benefits of the tube method are identification 
of all antibodies present and the ability to enhance testing 
using various potentiating factors, incubation times, and 
temperature phases. The tube method provides critical data 
for determining antibody clinical significance. However, it 
is beneficial for a reference laboratory to have gel and solid-
phase methodologies available for comparison because many 
referring hospitals use these methods for initial antibody 
detection. Overall, the tube method was the most reliable 
method for antibody identification in our reference laboratory.
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